Fesoterodine Fumarate Tablet, Film Coated, Extended Release
Product Images NDC 31722-034

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 31722-034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Camber (Camber)

Camber (Camber)
FDA Label Image
Camberlogo (Camberlogo)
FDA Label Image

Fesoterodine-4mg-30s (Fesoterodine 4mg 30s)

Fesoterodine-4mg-30s (Fesoterodine 4mg 30s)
Each extended-release tablet of CAMBE contains 4 mg of fesoterodine fumarate. The usual dosage information can be found in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F) in a controlled room temperature area and protected from moisture. They should be swallowed whole and not chewed, divided, or crushed. For more details, contact Camber Pharmaceuticals, Inc. at 1-866-495-1995.*
FDA Label Image

Fesoterodine-8mg-30s (Fesoterodine 8mg 30s)

Fesoterodine-8mg-30s (Fesoterodine 8mg 30s)
This text provides information about a medication called CAMBE, which is an extended-release, film-coated tablet containing 8 mg of fesoterodine fumarate. The usual dosage details can be found in the package insert. It is recommended to store the tablets at a temperature range of 20°C to 25°C (68°F to 77°F) and to protect them from moisture. The tablets should be swallowed whole and not chewed, divided, or crushed. The contact number for the U.S. is provided as 1-866-495-1995. The tablets are manufactured by Annora Pharma Pvt. Ltd. in Sangareddy, Telangana, India, and for distribution by Camber Pharmaceuticals, Inc. in Piscataway, NJ, USA.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This is not-available.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
This is a figure illustrating the change in urge incontinence episodes per 24 hours in Study 1. The data shows the reduction in episodes of urge incontinence among participants after treatment with Fesoterodine Fumarate extended-release tablets at different doses - 4 mg and 8 mg. The graph displays a decrease in episodes over time for both treatment groups.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This text appears to mention a study related to urge incontinence episodes over a 24 hour period. It includes a placebo group, a group using Famtenna for 4 grams, and a group using Festedin. The study seems to be comparing the effectiveness of these treatments in reducing urge incontinence episodes.*
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.